Yes, the four indications are excluded- and given that it is what Neuren wants to target it should have zero effect re valuations. Also, if Neuren wanted to go after another indication, I don't think it would be retrospective ie Acadia would surely have to have had commenced planning/trials at least?
Ann: Q2 2023 quarterly activity and cash flow report, page-11
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.81 |
Change
1.270(10.1%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.96 | $13.88 | $12.91 | $3.770M | 281.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27 | $13.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.81 | 79 | 1 |
View Market Depth
| Last trade - 10.25am 26/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |